Search

Your search keyword '"Hsu, Po-Yao"' showing total 160 results
Start Over Author "Hsu, Po-Yao"
160 results on '"Hsu, Po-Yao"'

1. Severity of fatty liver is highly correlated with the risk of hypertension and diabetes: a cross-sectional and longitudinal cohort study

Author

Shih, Chin-I., Wu, Kuan-Ta, Hsieh, Meng-Hsuan, Yang, Jeng-Fu, Chen, Yi-Yu, Tsai, Wei-Lun, Chen, Wen-Chi, Liang, Po-Cheng, Wei, Yu-Ju, Tsai, Pei-Chien, Hsu, Po-Yao, Hsieh, Ming-Yen, Lin, Yi-Hung, Jang, Tyng-Yuan, Wang, Chih-Wen, Yeh, Ming-Lun, Huang, Chung-Feng, Huang, Jee-Fu, Dai, Chia-Yen, Ho, Chi-Kung, Chuang, Wan-Long, and Yu, Ming-Lung

Published
2024
Full Text
View/download PDF

3. FRI-280 Dynamic of cardiometabolic components are highly correlated with the risk of hypertension and diabetes among patients with metabolic dysfunction-associated steatotic liver disease

Author

Shih, Chin-I, primary, Yeh, Ming-Lun, additional, Wu, Kuan-Ta, additional, Hsieh, Meng-Hsuan, additional, Yang, Jeng-Fu, additional, Chen, Yi-Yu, additional, Tsai, Wei-Lun, additional, Chen, Wen-Chi, additional, Liang, Po-Cheng, additional, Wei, Yu-Ju, additional, Tsai, Pei-Chien, additional, Cheng, Ya-Yun, additional, Hsu, Po-Yao, additional, Hsieh, Ming-Yen, additional, Lin, Yi-Hung, additional, Jang, Tyng-Yuan, additional, Wang, Chih-Wen, additional, Huang, Chung-Feng, additional, Huang, Jee-Fu, additional, Dai, Chia-Yen, additional, Ho, Chi-Kung, additional, Chuang, Wan-Long, additional, Chang, Wei-Ting, additional, and Yu, Ming-Lung, additional

Published
2024
Full Text
View/download PDF

4. FRI-271 Hepatitis C infection increases the risk of new-onset HTN and DM among patients with metabolic dysfunction-associated steatotic liver disease

Author

Shih, Ping-Tsung, primary, Shih, Chin-I, additional, Wu, Kuan-Ta, additional, Hsieh, Meng-Hsuan, additional, Yang, Jeng-Fu, additional, Chen, Yi-Yu, additional, Tsai, Wei-Lun, additional, Chen, Wen-Chi, additional, Liang, Po-Cheng, additional, Wei, Yu-Ju, additional, Tsai, Pei-Chien, additional, Hsu, Po-Yao, additional, Hsieh, Ming-Yen, additional, Lin, Yi-Hung, additional, Jang, Tyng-Yuan, additional, Wang, Chih-Wen, additional, Yeh, Ming-Lun, additional, Huang, Chung-Feng, additional, Huang, Jee-Fu, additional, Dai, Chia-Yen, additional, Ho, Chi-Kung, additional, Chuang, Wan-Long, additional, and Yu, Ming-Lung, additional

Published
2024
Full Text
View/download PDF

7. Third vaccine boosters and anti‐S‐IgG levels: A comparison of homologous and heterologous responses and poor immunogenicity in hepatocellular carcinoma

Author

Wang, Chih‐Wen, primary, Huang, Chung‐Feng, additional, Jang, Tyng‐Yuan, additional, Yeh, Ming‐Lun, additional, Liang, Po‐Cheng, additional, Wei, Yu‐Ju, additional, Hsu, Po‐Yao, additional, Huang, Ching‐I., additional, Hsieh, Ming‐Yen, additional, Lin, Yi‐Hung, additional, Huang, Jee‐Fu, additional, Dai, Chia‐Yen, additional, Chuang, Wan‐Long, additional, and Yu, Ming‐Lung, additional

Published
2024
Full Text
View/download PDF

8. Performance of noninvasive seromarkers in predicting liver fibrosis among MAFLD patients with or without viral hepatitis

Author

Huang, Chung‐Feng, primary, Liang, Po‐Cheng, additional, Wang, Chih‐Wen, additional, Jang, Tyng‐Yuan, additional, Hsu, Po‐Yao, additional, Tsai, Pei‐Chien, additional, Wei, Yu‐Ju, additional, Yeh, Ming‐Lun, additional, Hsieh, Ming‐Yen, additional, Lin, Yi‐Hung, additional, Huang, Chao‐Kuan, additional, Dai, Chia‐Yen, additional, Huang, Jee‐Fu, additional, Chuang, Wan‐Long, additional, and Yu, Ming‐Lung, additional

Published
2024
Full Text
View/download PDF

10. Effects of Sling Exercise for Neck Pain: A Systematic Review and Meta-Analysis

Author

Lin, Kuan-Yin, Tsai, Yi-Ju, Hsu, Po-Yao, Tsai, Cheng-Shin, and Kuo, Yi-Liang

Subjects
Exercise therapy -- Testing, Therapeutics, Experimental -- Evaluation, Neck pain -- Care and treatment
Abstract

Objective. The purpose of this review was to evaluate the effects of sling exercise on pain intensity, disability, and health-related quality of life in adults with neck pain. Methods. The Cochrane Central Register of Controlled Trials, EMBASE, Physiotherapy Evidence Database (PEDro), and 6 other databases were searched from inception to July 2020. The reference lists of relevant articles to identify additional trials were also screened. Randomized controlled trials were included if they investigated the effects of sling suspension therapy in patients with neck pain, including mechanical neck disorders, cervicogenic headache, and neck disorders with radicular findings. Studies were required to be published in English or Chinese. The methodological quality and levels of evidence of studies were assessed using the PEDro scale and the Grading of Recommendations Assessment, Development and Evaluation approach, respectively. The random-effects model was used to perform meta-analyses. Results. Eleven randomized controlled trials were included (n = 595). The mean total PEDro score was 4.64 (SD =1.21) of 10, which indicated a fair methodological quality. The intervention groups showed significant improvements in pain intensity (SMD = -1.23; 95% CI = -1.8 8 t o -0.58) immediately postintervention compared with the control groups. No significant effects were found for disability, cervical range of motion, and health-related quality of life. However, sensitivity analyses revealed significant short-term improvements in pain intensity, disability, and cervical range of motion and sustained effects on disability at intermediate-term follow-up. Conclusion. Sling exercise appears to be beneficial for improvements in pain intensity (moderate- to low-level evidence) among patients with neck pain. However, no definitive conclusion could be made regarding the effect of sling exercise for neck pain due to methodological limitations and high heterogeneity in the included studies. Impact. This review provides overall moderate- to very low-level evidence for health care professionals who may consider including sling exercise in the intervention program for patients with neck pain. Keywords: Disability, Exercise Therapy, Neck Pain, Systematic Review, Sling Exercise, Introduction Neck pain is a prevalent condition and has a 1-year prevalence of 30% to 50% and a lifetime prevalence of 14.2% to 71% (.1-3) People with neck pain demonstrate [...]

Published
2021
Full Text
View/download PDF

11. Air pollution associate with advanced hepatic fibrosis among patients with chronic liver disease

Author

Jang, Tyng‐Yuan, primary, Ho, Chi‐Chang, additional, Liang, Po‐Cheng, additional, Wu, Chih‐Da, additional, Wei, Yu‐Ju, additional, Tsai, Pei‐Chien, additional, Hsu, Po‐Yao, additional, Hsieh, Ming‐Yen, additional, Lin, Yi‐Hung, additional, Hsieh, Meng‐Hsuan, additional, Wang, Chih‐Wen, additional, Yang, Jeng‐Fu, additional, Yeh, Ming‐Lun, additional, Huang, Chung‐Feng, additional, Chuang, Wan‐Long, additional, Huang, Jee‐Fu, additional, Cheng, Ya‐Yun, additional, Dai, Chia‐Yen, additional, Chen, Pau‐Chung, additional, and Yu, Ming‐Lung, additional

Published
2023
Full Text
View/download PDF

12. Patient‐centered and integrated outreach care for chronic hepatitis C patients with serious mental illness in Taiwan

Author

Huang, Chung‐Feng, primary, Jang, Tyng‐Yuan, additional, Yu, Shun‐Chieh, additional, Huang, Shin‐Chung, additional, Ho, Shao‐Lun, additional, Yeh, Ming‐Lun, additional, Wang, Chih‐Wen, additional, Liang, Po‐Cheng, additional, Wei, Yu‐Ju, additional, Hsu, Po‐Yao, additional, Huang, Ching‐I, additional, Hsieh, Ming‐Yen, additional, Lin, Yi‐Hung, additional, Yu, Sung‐Lin, additional, Wu, Pey‐Fang, additional, Chen, Yu‐Han, additional, Chien, Shin‐Chi, additional, Huang, Jee‐Fu, additional, Dai, Chia‐Yen, additional, Chuang, Wan‐Long, additional, Wang, Tso‐Jen, additional, and Yu, Ming‐Lung, additional

Published
2023
Full Text
View/download PDF

14. Changing epidemiology and viral interplay of hepatitis B, C and D among injecting drug user-dominant prisoners in Taiwan

Author

Lu, Ming-Ying, Chen, Chun-Ting, Shih, Yu-Lueng, Tsai, Pei-Chien, Hsieh, Meng-Hsuan, Huang, Chung-Feng, Yeh, Ming-Lun, Huang, Ching-I, Wang, Shu-Chi, Tsai, Yi-Shan, Ko, Yu-Min, Lin, Ching-Chih, Chen, Kuan-Yu, Wei, Yu-Ju, Hsu, Po-Yao, Hsu, Cheng-Ting, Jang, Tyng-Yuan, Liu, Ta-Wei, Liang, Po-Cheng, Hsieh, Ming-Yen, Lin, Zu-Yau, Chen, Shinn-Cherng, Huang, Jee-Fu, Dai, Chia-Yen, Chuang, Wan-Long, Yu, Ming-Lung, and Chang, Wen-Yu

Published
2021
Full Text
View/download PDF

15. Role of hepatitis D virus infection in development of hepatocellular carcinoma among chronic hepatitis B patients treated with nucleotide/nucleoside analogues

Author

Jang, Tyng-Yuan, Wei, Yu-Ju, Liu, Ta-Wei, Yeh, Ming-Lun, Liu, Shu-Fen, Hsu, Cheng-Ting, Hsu, Po-Yao, Lin, Yi-Hung, Liang, Po-Cheng, Hsieh, Meng-Hsuan, Ko, Yu-Min, Tsai, Yi-Shan, Chen, Kuan-Yu, Lin, Ching-Chih, Tsai, Pei-Chien, Wang, Shu-Chi, Huang, Ching-I., Lin, Zu-Yau, Chen, Shinn-Cherng, Chuang, Wan-Long, Huang, Jee-Fu, Dai, Chia-Yen, Huang, Chung-Feng, and Yu, Ming-Lung

Published
2021
Full Text
View/download PDF

16. Third vaccine boosters and anti‐S‐IgGlevels: A comparison of homologous and heterologous responses and poor immunogenicity in hepatocellular carcinoma

Author

Wang, Chih‐Wen, Huang, Chung‐Feng, Jang, Tyng‐Yuan, Yeh, Ming‐Lun, Liang, Po‐Cheng, Wei, Yu‐Ju, Hsu, Po‐Yao, Huang, Ching‐I., Hsieh, Ming‐Yen, Lin, Yi‐Hung, Huang, Jee‐Fu, Dai, Chia‐Yen, Chuang, Wan‐Long, and Yu, Ming‐Lung

Abstract

The immune response of patients with chronic liver disease tends to be lower after receiving their second coronavirus disease 2019 (COVID‐19) vaccine dose, but the effect of a third vaccine dose on their immune response is currently unknown. We recruited 722 patients without previous severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection from three hospitals. The patients received homologous (MMM) and heterologous (AZAZBNT, AZAZM) boosters, where AZ, BNT, and M denoted the AZD1222, BNT162b2, and mRNA‐1273 vaccines, respectively. Serum IgG spike antibody levels were measured at a mean 1.5 ± 0.7 (visit 1) and 5.0 ± 0.5 (visit 2) months after the third vaccine booster. A threshold of 4160 AU/mL was considered significant antibody activity. In both visits, the patients who received the MMM booster had higher anti‐S‐IgG levels than those who received the AZAZBNT and AZAZM boosters. Patients with active hepatocellular carcinoma (HCC) had lower anti‐S‐IgG levels than the control group (761.6 vs. 1498.2 BAU/mL; p= 0.019) at visit 1. The anti‐S‐IgG levels decreased significantly at visit 2. The patients with significant antibody activity had a lower rate of liver cirrhosis with decompensation (0.7% decompensation vs. 8.0% non‐decompensation and 91.3% non‐liver cirrhosis, p= 0.015), and active HCC (1.5% active HCC vs. 3.7% non‐active HCC and 94.7% non‐HCC, p< 0.001). Receiving the MMM booster regimen (OR = 10.67, 95% CI 5.20–21.91, p< 0.001) increased the odds of having significant antibody activity compared with the AZAZBNT booster regimen. Patients with active HCC had a reduced immune response to the third COVID‐19 vaccine booster. These findings underscore the importance of booster vaccinations, especially in immunocompromised patients, with superior efficacy observed with the homologous mRNA‐1273 regimen.

Published
2024
Full Text
View/download PDF

17. Performance of noninvasive seromarkers in predicting liver fibrosis among MAFLDpatients with or without viral hepatitis

Author

Huang, Chung‐Feng, Liang, Po‐Cheng, Wang, Chih‐Wen, Jang, Tyng‐Yuan, Hsu, Po‐Yao, Tsai, Pei‐Chien, Wei, Yu‐Ju, Yeh, Ming‐Lun, Hsieh, Ming‐Yen, Lin, Yi‐Hung, Huang, Chao‐Kuan, Dai, Chia‐Yen, Huang, Jee‐Fu, Chuang, Wan‐Long, and Yu, Ming‐Lung

Abstract

The accuracy of noninvasive seromarkers in predicting liver fibrosis in metabolic dysfunction‐associated fatty liver disease (MAFLD) patients with or without viral hepatitis is elusive. The AST to platelet ratio index (APRI), fibrosis‐4 index (FIB‐4), and NAFLD fibrosis score (NFS) were assessed in 871 MAFLD patients who received elastography in a viral hepatitis‐endemic area. The area under the receiver operating characteristic (AUROC) curve increased substantially with increasing fibrotic stage across the three biomarkers. APRI (AUROC range 0.73–0.80) and FIB‐4 (AUROC range 0.66–0.82) performed better than NFS (AUROC range 0.63–0.75). When patients were divided into viral and non‐viral MAFLD groups, a better AUROC of APRI (range 0.76–0.80) and FIB‐4 (range 0.68–0.78) than NFS (range 0.62–70) existed only in viral MALFD but not in non‐viral MAFLD. Regarding the NFS, the AUROC was higher in non‐viral MAFLD (range 0.69–0.86) and outperformed viral MAFLD at all fibrotic stages. The accuracy in predicting liver fibrosis increased with the advancement of liver disease for the three biomarkers. NFS exerted better diagnostic accuracy in non‐viral than in viral MAFLD patients across different fibrotic stages. The best accuracy was 91.1% using the cutoff value of −9.98 for the NFS in predicting liver cirrhosis in non‐viral MAFLD patients. The APRI and FIB‐4 performed better than the NFS in predicting liver fibrosis in MAFLD as a whole. The suboptimal performance and accuracy of the NFS existed only in viral MAFLD patients. Caution should be taken when assessing the NFS in MAFLD patients with viral hepatitis.

Published
2024
Full Text
View/download PDF

19. Air pollution associate with advanced hepatic fibrosis among patients with chronic liver disease.

Author

Jang, Tyng‐Yuan, Ho, Chi‐Chang, Liang, Po‐Cheng, Wu, Chih‐Da, Wei, Yu‐Ju, Tsai, Pei‐Chien, Hsu, Po‐Yao, Hsieh, Ming‐Yen, Lin, Yi‐Hung, Hsieh, Meng‐Hsuan, Wang, Chih‐Wen, Yang, Jeng‐Fu, Yeh, Ming‐Lun, Huang, Chung‐Feng, Chuang, Wan‐Long, Huang, Jee‐Fu, Cheng, Ya‐Yun, Dai, Chia‐Yen, Chen, Pau‐Chung, and Yu, Ming‐Lung

Subjects
AIR pollution, HEPATIC fibrosis, CHRONICALLY ill, AIR pollutants, CHRONIC hepatitis B
Abstract

We aimed to investigate the association between air pollution and advanced fibrosis among patients with metabolic associated fatty liver disease (MAFLD) and chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) infections. A total of 1376 participants who were seropositive for HBV surface antigen (HBsAg) or antibodies to HCV (anti‐HCV) or had abnormal liver function in a community screening program from 2019 to 2021 were enrolled for the assessment of liver fibrosis using transient elastography. Daily estimates of air pollutants (particulate matter ≤2.5 μm in diameter [PM2.5], nitrogen dioxide [NO2], ozone [O3] and benzene) were aggregated into mean estimates for the previous year based on the date of enrolment. Of the 1376 participants, 767 (52.8%) and 187 (13.6) had MAFLD and advanced fibrosis, respectively. A logistic regression analysis revealed that the factors associated with advanced liver fibrosis were HCV viremia (odds ratio [OR], 3.13; 95% confidence interval [CI], 2.05–4.77; p < 0.001), smoking (OR, 1.79; 95% CI, 1.16–2.74; p = 0.01), age (OR, 1.04; 95% CI, 1.02–1.05; p < 0.001) and PM2.5 (OR, 1.10; 95% CI, 1.05–1.16; p < 0.001). Linear regression analysis revealed that LSM was independently correlated with PM2.5 (β: 0.134; 95% CI: 0.025, 0.243; p = 0.02). There was a dose‐dependent relationship between different fibrotic stages and the PM2.5 level (the PM2.5 level in patients with fibrotic stages 0, 1–2 and 3–4: 27.9, 28.4, and 29.3 μg/m3, respectively; trend p < 0.001). Exposure to PM2.5, as well as HBV and HCV infections, is associated with advanced liver fibrosis in patients with MAFLD. There was a dose‐dependent correlation between PM2.5 levels and the severity of hepatic fibrosis. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

20. Patient‐centered and integrated outreach care for chronic hepatitis C patients with serious mental illness in Taiwan.

Author

Huang, Chung‐Feng, Jang, Tyng‐Yuan, Yu, Shun‐Chieh, Huang, Shin‐Chung, Ho, Shao‐Lun, Yeh, Ming‐Lun, Wang, Chih‐Wen, Liang, Po‐Cheng, Wei, Yu‐Ju, Hsu, Po‐Yao, Huang, Ching‐I, Hsieh, Ming‐Yen, Lin, Yi‐Hung, Yu, Sung‐Lin, Wu, Pey‐Fang, Chen, Yu‐Han, Chien, Shin‐Chi, Huang, Jee‐Fu, Dai, Chia‐Yen, and Chuang, Wan‐Long

Subjects
PEOPLE with mental illness, CHRONIC hepatitis C, HEPATITIS C, HEPATITIS C virus, DELAYED diagnosis, DISEASE risk factors, PSYCHIATRIC nursing
Abstract

Patients with serious mental illness have a higher risk of hepatitis C virus (HCV) infection but suboptimal HCV care. The current study aimed to facilitate HCV treatment uptake by implementing an integrated outreach care model. Multidisciplinary outreach screening followed by HCV reflex testing and onsite treatment for schizophrenia patients was accomplished through the coordination of nongovernmental organizations, remote specialists, and local care providers. The objective was microelimination effectiveness, defined as the multiplication of the rates of anti‐HCV antibodies screening, accurate HCV RNA diagnosis, treatment allocation, treatment completion, and sustained virological response (SVR12; no detectable HCV RNA throughout 12 weeks in the post‐treatment follow‐up period). A total of 1478 of the 2300 (64.3%) psychiatric patients received HCV mass screening. Seventy‐three (4.9%) individuals were seropositive for anti‐HCV antibodies. Of the 73 anti‐HCV seropositive patients, all (100%) received HCV reflex testing, and 29 (37.7%) patients had HCV viremia. Eight patients (34.8%) had advanced liver disease, including 3 with liver cirrhosis and 2 with newly diagnosed hepatocellular carcinoma. Twenty‐three of the 24 (95.8%) patients who stayed in the healthcare system received and completed 8 weeks of glecaprevir/pibrentasvir treatment and post‐treatment follow‐up without significant DDIs or adverse events. The SVR12 rate was 100%. The microelimination effectiveness in the current study was 61.6%. Individuals with serious mental illness are underserved and suffer from diagnostic delays. This patient‐centered and integrated outreach program facilitated HCV care in this marginalized population. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

21. The interplay of metabolic dysfunction‐associated fatty liver disease and viral hepatitis on liver disease severity: A large community‐based study in a viral endemic area.

Author

Huang, Chung‐Feng, Liang, Po‐Cheng, Tsai, Pei‐Chien, Wei, Yu‐Ju, Huang, Ching‐I, Wang, Chih‐Wen, Jang, Tyng‐Yuan, Yeh, Ming‐Lun, Hsu, Po‐Yao, Hsieh, Ming‐Yen, Lin, Yi‐Hung, Dai, Chia‐Yen, Chuang, Wan‐Long, Huang, Jee‐Fu, and Yu, Ming‐Lung

Subjects
FATTY liver, VIRAL hepatitis, LIVER diseases, VIRUS diseases, HEPATITIS C virus
Abstract

Background and Aim: The prevalence of metabolic dysfunction‐associated fatty liver disease (MAFLD) and its interplay with hepatitis B virus (HBV) and hepatitis C virus (HCV) in terms of liver disease severity is elusive. Methods: A mass surveillance program was conducted in a viral hepatitis endemic area. The objective was to identify MAFLD/non‐MAFLD subjects with advanced liver disease. Results: Two thousand two hundred and forty‐two (41.7%) of the 5378 subjects were identified as having MAFLD, and 375 (7.0%) had advanced liver disease. The proportions of anti‐HCV and HBsAg seropositivity were 19.3% and 9.7%, respectively. The proportions of advanced fibrosis in subjects with non‐viral hepatitis (NBNC), HBV and HCV infection were 2.8%, 5.7% and 23.4%, respectively. Subjects with MAFLD had a significantly higher proportion of advanced fibrosis (8.7% vs 5.7%, P < 0.001). Factors associated with advanced fibrosis included age (odds ratio [OR]/95% confidence interval [CI]: 4.8/3.7–6.0, P < 0.001), male sex (OR/CI: 1.3/1.0–1.7, P = 0.019), anti‐HCV seropositivity (OR/CI: 5.9/4.6–7.5, P = 0.019), MAFLD‐lean metabolic dysregulation (MS) (OR/CI: 2.6/1.3–5.2, P = 0.005; compared with the non‐MAFLD group) and MAFLD‐diabetes (OR/CI: 1.5/1.1–2.1, P = 0.008; compared with the non‐MAFLD group). MAFLD did not aggravate liver disease severity in patients with viral hepatitis. However, among NBNC subjects, factors associated with advanced liver disease included MAFLD‐lean MS group (OR/CI: 9.1/2.4–34.6, P = 0.001; compared with non‐MAFLD group) and MAFLD‐DM group (OR/CI: 2.0/1.2–3.2, P = 0.004; compared with non‐MAFLD group). Conclusions: MAFLD patients with diabetes and metabolic dysregulation had a higher risk of advanced liver disease. The effect was more significant in non‐viral hepatitis subjects in a community level. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

22. The interplay of metabolic dysfunction‐associated fatty liver disease and viral hepatitis on liver disease severity: A large community‐based study in a viral endemic area

Author

Huang, Chung‐Feng, primary, Liang, Po‐Cheng, additional, Tsai, Pei‐Chien, additional, Wei, Yu‐Ju, additional, Huang, Ching‐I, additional, Wang, Chih‐Wen, additional, Jang, Tyng‐Yuan, additional, Yeh, Ming‐Lun, additional, Hsu, Po‐Yao, additional, Hsieh, Ming‐Yen, additional, Lin, Yi‐Hung, additional, Dai, Chia‐Yen, additional, Chuang, Wan‐Long, additional, Huang, Jee‐Fu, additional, and Yu, Ming‐Lung, additional

Published
2023
Full Text
View/download PDF

23. Impact of comorbidities on the serological response to COVID-19 vaccination in a Taiwanese cohort

Author

Huang, Chung-Feng, primary, Jang, Tyng-Yuan, additional, Wu, Ping-Hsun, additional, Kuo, Mei-Chuan, additional, Yeh, Ming-Lun, additional, Wang, Chih-Wen, additional, Liang, Po-Cheng, additional, Wei, Yu-Ju, additional, Hsu, Po-Yao, additional, Huang, Ching-I, additional, Hsieh, Ming-Yen, additional, Lin, Yi-Hung, additional, Hsiao, Hui-Hua, additional, Hsu, Chin-Mu, additional, Huang, Chien-Tzu, additional, Lee, Chun-Yuan, additional, Chen, Yen-Hsu, additional, Chen, Tun-Chieh, additional, Lin, Kun-Der, additional, Wang, Shuo-Hung, additional, Wang, Sheng-Fan, additional, Huang, Jee-Fu, additional, Dai, Chia-Yen, additional, Chuang, Wan-Long, additional, and Yu, Ming-Lung, additional

Published
2023
Full Text
View/download PDF

24. Patient‐centered and integrated outreach care for chronic hepatitis Cpatients with serious mental illness in Taiwan

Author

Huang, Chung‐Feng, Jang, Tyng‐Yuan, Yu, Shun‐Chieh, Huang, Shin‐Chung, Ho, Shao‐Lun, Yeh, Ming‐Lun, Wang, Chih‐Wen, Liang, Po‐Cheng, Wei, Yu‐Ju, Hsu, Po‐Yao, Huang, Ching‐I, Hsieh, Ming‐Yen, Lin, Yi‐Hung, Yu, Sung‐Lin, Wu, Pey‐Fang, Chen, Yu‐Han, Chien, Shin‐Chi, Huang, Jee‐Fu, Dai, Chia‐Yen, Chuang, Wan‐Long, Wang, Tso‐Jen, and Yu, Ming‐Lung

Abstract

Patients with serious mental illness have a higher risk of hepatitis C virus (HCV) infection but suboptimal HCV care. The current study aimed to facilitate HCV treatment uptake by implementing an integrated outreach care model. Multidisciplinary outreach screening followed by HCV reflex testing and onsite treatment for schizophrenia patients was accomplished through the coordination of nongovernmental organizations, remote specialists, and local care providers. The objective was microelimination effectiveness, defined as the multiplication of the rates of anti‐HCV antibodies screening, accurate HCV RNA diagnosis, treatment allocation, treatment completion, and sustained virological response (SVR12; no detectable HCV RNA throughout 12 weeks in the post‐treatment follow‐up period). A total of 1478 of the 2300 (64.3%) psychiatric patients received HCV mass screening. Seventy‐three (4.9%) individuals were seropositive for anti‐HCV antibodies. Of the 73 anti‐HCV seropositive patients, all (100%) received HCV reflex testing, and 29 (37.7%) patients had HCV viremia. Eight patients (34.8%) had advanced liver disease, including 3 with liver cirrhosis and 2 with newly diagnosed hepatocellular carcinoma. Twenty‐three of the 24 (95.8%) patients who stayed in the healthcare system received and completed 8 weeks of glecaprevir/pibrentasvir treatment and post‐treatment follow‐up without significant DDIs or adverse events. The SVR12 rate was 100%. The microelimination effectiveness in the current study was 61.6%. Individuals with serious mental illness are underserved and suffer from diagnostic delays. This patient‐centered and integrated outreach program facilitated HCV care in this marginalized population.

Published
2024
Full Text
View/download PDF

25. Therapy as prevention toward HCV elimination in maintenance hemodialysis: a multi-center, prospective cohort study.

Author

Huang, Chung-Feng, Dai, Chia-Yen, Wang, Chih-Wen, Liang, Po-Cheng, Wei, Yu-Ju, Tsai, Pei-Chien, Jang, Tyng-Yuan, Hsu, Po-Yao, Lee, Jia-Jung, Niu, Sheng-Wen, Huang, Jiun-Chi, Yeh, Ming-Lun, Huang, Ching-I, Hsieh, Ming-Yen, Lin, Yi-Hung, Chen, Szu-Chia, Chiu, Yi-Wen, Huang, Jee-Fu, Chang, Jer-Ming, and Hwang, Shang-Jyh

Subjects
HEPATITIS C virus, PATIENT experience, COHORT analysis, HEMODIALYSIS, LONGITUDINAL method
Abstract

Background The World Health Organization has established interim guidance for hepatitis C virus (HCV) elimination. We aimed to prove the concept of "treatment as prevention" by conducting a prospective HCV elimination program for hemodialysis (HD) patients. Methods A universal HCV screen was launched in 22 HD centers in 2019. HCV-viremic patients were linked to care with direct-acting antivirals (DAAs). The second screen was performed in 2021 to evaluate the effect of link-to-care in lowering the prevalence of HCV viremia and the incidence of HCV new/re-infections. Results Of 2336 patients enrolled in the first screening in 2019, 320 (13.7%) were seropositive for anti-HCV and 181 (7.7%) were HCV-viremic. Of 152 patients successfully linked to treat with DAA, 140 (92.1%) patients achieved a sustained virological response. Of them, 1733 patients participated in the second surveillance. Five anti-HCV-negative patients experienced anti-HCV seroconversion. Of 119 DAA-cured patients and 102 spontaneous HCV clearance patients, none had HCV reinfection. The annual incidence of HCV new infection was 0.1%. Sixty-one of the 620 (9.8%) newly enrolled patients were anti-HCV-seropositive in the second survey. The overall HCV-viremic rate decreased from 7.7% in 2019 to 0.6% (15/2353) in 2021. At the institutional level, 45.5% (10/22) eradicated HCV and 82% (18/22) of HD units had no HCV new infections or reinfections. Conclusions The link-to-care project proved the concept of "treatment as prevention" by which HCV microelimination helps to prevent reinfection and new infections in the HD population. Trial registration: ClinicalTrials.gov identifier: NCT03803410 and NCT03891550. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

26. Impact of comorbidities on the serological response to COVID-19 vaccination in Taiwan

Author

Huang, Chung-Feng, primary, Jang, Tyng-Yuan, additional, Wu, Ping-Hsun, additional, Kuo, Mei-Chuan, additional, Yeh, Ming-Lun, additional, Wang, Chih-Wen, additional, Liang, Po-Cheng, additional, Wei, Yu-Ju, additional, Hsu, Po-Yao, additional, Huang, Ching-I, additional, Hsieh, Ming-Yen, additional, Lin, Yi-Hung, additional, Hsiao, Hui-Hua, additional, Hsu, Chin-Mu, additional, Huang, Chien-Tzu, additional, Lee, Chun-Yuan, additional, Chen, Yen-Hsu, additional, Chen, Tun-Chieh, additional, Lin, Kun-Der, additional, Wang, Shuo-Hung, additional, Wang, Sheng-Fan, additional, Huang, Jee-Fu, additional, Dai, Chia-Yen, additional, Chuang, Wan-Long, additional, and Yu, Ming-Lung, additional

Published
2023
Full Text
View/download PDF

27. Effects of Achieving SVR on Clinical Characteristics and Surgical Outcomes in Patients Who Developed Early-Stage HCV-Related Hepatocellular Carcinoma and Received Curative Resection: Preoperative versus Postoperative SVR

Author

Hsu, Po-Yao, primary, Liang, Po-Cheng, additional, Huang, Ching-I, additional, Hsieh, Meng-Hsuan, additional, Tsai, Yi-Shan, additional, Lin, Tzu-Chun, additional, Yeh, Ming-Lun, additional, Huang, Chung-Feng, additional, Wang, Chih-Wen, additional, Jang, Tyng-Yuan, additional, Lin, Yi-Hung, additional, Lin, Zu-Yau, additional, Chuang, Wan-Long, additional, and Dai, Chia-Yen, additional

Published
2022
Full Text
View/download PDF

28. Amelioration of glucose intolerance through directly acting antiviral agents in chronic hepatitis C cirrhotic patients without overt diabetes

Author

Jang, Tyng‐Yuan, primary, Lin, Yi‐Hung, additional, Liang, Po‐Cheng, additional, Yeh, Ming‐Lun, additional, Huang, Ching‐I, additional, Liu, Ta‐Wei, additional, Wei, Yu‐Ju, additional, Hsu, Po‐Yao, additional, Yang, Jeng‐Fu, additional, Hou, Nai‐Jen, additional, Wang, Chih‐Wen, additional, Hsieh, Ming‐Yen, additional, Lin, Zu‐Yau, additional, Huang, Chung‐Feng, additional, Huang, Jee‐Fu, additional, Dai, Chia‐Yen, additional, Chuang, Wan‐Long, additional, and Yu, Ming‐Lung, additional

Published
2022
Full Text
View/download PDF

29. Low disease awareness as a contributing factor to the high prevalence of hepatitis C infection in Tzukuan, a hyperendemic area of southern Taiwan

Author

Tsai, Pei‐Chien, primary, Dai, Chia‐Yen, additional, Huang, Ching‐I, additional, Yeh, Ming‐Lun, additional, Huang, Chung‐Feng, additional, Hsieh, Meng‐Hsuan, additional, Yang, Jeng‐Fu, additional, Hsu, Po‐Yao, additional, Liang, Po‐Cheng, additional, Lin, Yi‐Hung, additional, Jang, Tyng‐Yuan, additional, Hsieh, Ming‐Yen, additional, Lin, Zu‐Yau, additional, Chen, Shinn‐Chern, additional, Huang, Jee‐Fu, additional, Yu, Ming‐Lung, additional, Chuang, Wan‐Long, additional, and Chang, Wen‐Yu, additional

Published
2022
Full Text
View/download PDF

30. Itemization difference of patient-reported outcome in patients with chronic liver disease

Author

Lin, Ming-Chieh, primary, Dai, Chia-Yen, additional, Huang, Chung-Feng, additional, Yeh, Ming-Lun, additional, Liu, Yi-Chan, additional, Hsu, Po-Yao, additional, Wei, Yu-Ju, additional, Lee, Pei-Lun, additional, Huang, Ching-I, additional, Liang, Po-Cheng, additional, Hsieh, Ming-Yen, additional, Hsieh, Meng-Hsuan, additional, Jang, Tyng-Yuan, additional, Lin, Zu-Yau, additional, Huang, Jee-Fu, additional, Yu, Ming-Lung, additional, and Chuang, Wan-Long, additional

Published
2022
Full Text
View/download PDF

31. Outreach onsite treatment with a simplified pangenotypic direct-acting anti-viral regimen for hepatitis C virus micro-elimination in a prison

Author

Chen, Chun-Ting, primary, Lu, Ming-Ying, additional, Hsieh, Meng-Hsuan, additional, Tsai, Pei-Chien, additional, Hsieh, Tsai-Yuan, additional, Yeh, Ming-Lun, additional, Huang, Ching-I, additional, Tsai, Yi-Shan, additional, Ko, Yu-Min, additional, Lin, Ching-Chih, additional, Chen, Kuan-Yu, additional, Wei, Yu-Ju, additional, Hsu, Po-Yao, additional, Hsu, Cheng-Ting, additional, Jang, Tyng-Yuan, additional, Liu, Ta-Wei, additional, Liang, Po-Cheng, additional, Hsieh, Ming-Yen, additional, Lin, Zu-Yau, additional, Huang, Chung-Feng, additional, Huang, Jee-Fu, additional, Dai, Chia-Yen, additional, Chuang, Wan-Long, additional, Shih, Yu-Lueng, additional, and Yu, Ming-Lung, additional

Published
2022
Full Text
View/download PDF

32. Dynamics of cytokines predicts risk of hepatocellular carcinoma among chronic hepatitis C patients after viral eradication

Author

Lu, Ming-Ying, primary, Yeh, Ming-Lun, additional, Huang, Ching-I, additional, Wang, Shu-Chi, additional, Tsai, Yi-Shan, additional, Tsai, Pei-Chien, additional, Ko, Yu-Min, additional, Lin, Ching-Chih, additional, Chen, Kuan-Yu, additional, Wei, Yu-Ju, additional, Hsu, Po-Yao, additional, Hsu, Cheng-Ting, additional, Jang, Tyng-Yuan, additional, Liu, Ta-Wei, additional, Liang, Po-Cheng, additional, Hsieh, Ming-Yen, additional, Lin, Zu-Yau, additional, Chen, Shinn-Cherng, additional, Huang, Chung-Feng, additional, Huang, Jee-Fu, additional, Dai, Chia-Yen, additional, Chuang, Wan-Long, additional, and Yu, Ming-Lung, additional

Published
2022
Full Text
View/download PDF

33. A People-Centered Decentralized Outreach Model Toward HCV Micro-Elimination in Hyperendemic Areas: COMPACT Study in SARS Co-V2 Pandemic

Author

Huang, Ching-i, primary, Liang, Po-Cheng, additional, Wei, Yu-Ju, additional, Tsai, Pei-Chien, additional, Hsu, Po-Yao, additional, Hsieh, Ming-Yen, additional, Liu, Ta-Wei, additional, Lin, Yi-Hung, additional, Hsieh, Meng-Hsuan, additional, Jang, Tyng-Yuan, additional, Wang, Chih-Wen, additional, Yang, Jeng-Fu, additional, Yeh, Ming-Lun, additional, Huang, Chung-Feng, additional, Dai, Chia-Yen, additional, Chuang, Wan-Long, additional, Huang, Jee-Fu, additional, and Yu, Ming-Lung, additional

Published
2022
Full Text
View/download PDF

34. Towards a safe hospital: hepatitis C in-hospital micro-elimination program (HCV-HELP study)

Author

Huang, Jee-Fu, primary, Hsieh, Ming-Yen, additional, Wei, Yu-Ju, additional, Hung, Jen-Yu, additional, Huang, Hsuan-Ti, additional, Huang, Ching-I, additional, Yeh, Ming-Lun, additional, Huang, Chung-Feng, additional, Jang, Tyng-Yuan, additional, Hsu, Po-Yao, additional, Liang, Po-Cheng, additional, Dai, Chia-Yen, additional, Lin, Zu-Yau, additional, Yu, Ming-Lung, additional, and Chuang, Wan-Long, additional

Published
2021
Full Text
View/download PDF

35. Regorafenib for Taiwanese patients with unresectable hepatocellular carcinoma after sorafenib failure: Impact of alpha‐fetoprotein levels

Author

Hsu, Po‐Yao, primary, Cheng, Tzu‐Sheng, additional, Chuang, Shih‐Chang, additional, Chang, Wen‐Tsan, additional, Liang, Po‐Cheng, additional, Hsu, Cheng‐Ting, additional, Wei, Yu‐Ju, additional, Jang, Tyng‐Yuan, additional, Yeh, Ming‐Lun, additional, Huang, Ching‐I, additional, Lin, Yi‐Hung, additional, Wang, Chih‐Wen, additional, Hsieh, Ming‐Yen, additional, Hou, Nai‐Jen, additional, Hsieh, Meng‐Hsuan, additional, Tsai, Yi‐Shan, additional, Ko, Yu‐Min, additional, Lin, Ching‐Chih, additional, Chen, Kuan‐Yu, additional, Dai, Chia‐Yen, additional, Lin, Zu‐Yau, additional, Chen, Shinn‐Cherng, additional, Huang, Jee‐Fu, additional, Chuang, Wan‐Long, additional, Huang, Chung‐Feng, additional, and Yu, Ming‐Lung, additional

Published
2021
Full Text
View/download PDF

36. Seroreversion of hepatitis B surface antigen among subjects with resolved hepatitis B virus infection: A community‐based cohort study

Author

Yeh, Ming‐Lun, primary, Liang, Po‐Cheng, additional, Huang, Ching‐I, additional, Hsieh, Meng‐Hsuan, additional, Lin, Yi‐Hung, additional, Jang, Tyng‐Yuan, additional, Wei, Yu‐Ju, additional, Hsu, Po‐Yao, additional, Hsu, Cheng‐Ting, additional, Wang, Chih‐Wen, additional, Hsieh, Ming‐Yen, additional, Lin, Zu‐Yau, additional, Chen, Shinn‐Cherng, additional, Huang, Chung‐Feng, additional, Huang, Jee‐Fu, additional, Dai, Chia‐Yen, additional, Chuang, Wan‐Long, additional, and Yu, Ming‐Lung, additional

Published
2021
Full Text
View/download PDF

38. Comorbidities in patients with chronic hepatitis C and hepatitis B on hemodialysis

Author

Hsu, Po‐Yao, primary, Wei, Yu‐Ju, additional, Liang, Po‐Cheng, additional, Lee, Jia‐Jung, additional, Niu, Sheng‐Wen, additional, Huang, Jiun‐Chi, additional, Hsu, Cheng‐Ting, additional, Jang, Tyng‐Yuan, additional, Huang, Ching‐I, additional, Lin, Yi‐Hung, additional, Hsieh, Ming‐Yen, additional, Hsieh, Meng‐Hsuan, additional, Chen, Szu‐Chia, additional, Dai, Chia‐Yen, additional, Lin, Zu‐Yau, additional, Chen, Shinn‐Cherng, additional, Huang, Jee‐Fu, additional, Chang, Jer‐Ming, additional, Yeh, Ming‐Lun, additional, Huang, Chung‐Feng, additional, Chiu, Yi‐Wen, additional, Hwang, Shang‐Jyh, additional, Chuang, Wan‐Long, additional, and Yu, Ming‐Lung, additional

Published
2021
Full Text
View/download PDF

39. Genotype distribution, clinical characteristics, and racial differences observed in chronic hepatitis C patients in Pingtung, Taiwan

Author

Jang, Tyng-Yuan, primary, Liang, Po-Cheng, additional, Liu, Ta-Wei, additional, Wei, Yu-Ju, additional, Yeh, Ming-Lun, additional, Hsu, Cheng-Ting, additional, Hsu, Po-Yao, additional, Lin, Yi-Hung, additional, Hsieh, Meng-Hsuan, additional, Huang, Ching-I, additional, Huang, Chung-Feng, additional, Lin, Zu-Yau, additional, Chen, Shinn-Cherng, additional, Huang, Jee-Fu, additional, Dai, Chia-Yen, additional, Yu, Ming-Lung, additional, and Chuang, Wan-Long, additional

Published
2021
Full Text
View/download PDF

40. Significant amelioration of hepatitis C virus infection in a hyperendemic area: longitudinal evidence from the COMPACT Study in Taiwan

Author

Tsai, Pei-Chien, primary, Huang, Ching-I, additional, Yeh, Ming-Lun, additional, Huang, Chung-Feng, additional, Hsieh, Meng-Hsuan, additional, Yang, Jeng-Fu, additional, Hsu, Po-Yao, additional, Liang, Po-Cheng, additional, Lin, Yi-Hung, additional, Jang, Tyng Yuan, additional, Hsieh, Ming-Yen, additional, Dai, Chia-Yen, additional, Lin, Zu-Yau, additional, Chen, Shinn-Chern, additional, Huang, Jee-Fu, additional, Yu, Ming-Lung, additional, Chuang, Wan-Long, additional, and Chang, Wen-Yu, additional

Published
2021
Full Text
View/download PDF

41. Evolutionary seroepidemiology of viral hepatitis and the gap in hepatitis C care cascades among uraemic patients receiving haemodialysis in Taiwan—the Formosa‐Like Group

Author

Wei, Yu‐Ju, primary, Hsu, Po‐Yao, additional, Lee, Jia‐Jung, additional, Niu, Sheng‐Wen, additional, Huang, Jiun‐Chi, additional, Hsu, Cheng‐Ting, additional, Jang, Tyng‐Yuan, additional, Yeh, Ming‐Lun, additional, Huang, Ching‐I, additional, Liang, Po‐Cheng, additional, Lin, Yi‐Hung, additional, Hsieh, Ming‐Yen, additional, Hsieh, Meng‐Hsuan, additional, Chen, Szu‐Chia, additional, Dai, Chia‐Yen, additional, Lin, Zu‐Yau, additional, Chen, Shinn‐Cherng, additional, Huang, Jee‐Fu, additional, Chang, Jer‐Ming, additional, Hwang, Shang‐Jyh, additional, Chuang, Wan‐Long, additional, Huang, Chung‐Feng, additional, Chiu, Yi‐Wen, additional, and Yu, Ming‐Lung, additional

Published
2021
Full Text
View/download PDF

42. Concordance of SVR12, SVR24 and SVR durability in Taiwanese chronic hepatitis C patients with direct-acting antivirals

Author

Lin, Chuan-Pin, primary, Liang, Po-Cheng, additional, Huang, Ching-I, additional, Yeh, Ming-Lun, additional, Hsu, Po-Yao, additional, Hsu, Cheng-Ting, additional, Wei, Yu-Ju, additional, Liu, Ta-Wei, additional, Hsieh, Ming-Yen, additional, Hou, Nai-Jen, additional, Jang, Tyng-Yuang, additional, Lin, Yi-Hung, additional, Wang, Chih-Wen, additional, Lin, Zu-Yau, additional, Chen, Shinn-Cherng, additional, Huang, Chung-Feng, additional, Huang, Jee-Fu, additional, Dai, Chia-Yen, additional, Chuang, Wan-Long, additional, and Yu, Ming-Lung, additional

Published
2021
Full Text
View/download PDF

43. Scaling up the in-hospital hepatitis C virus care cascade in Taiwan

Author

Huang, Chung-Feng, primary, Wu, Pey-Fang, additional, Yeh, Ming-Lun, additional, Huang, Ching-I, additional, Liang, Po-Cheng, additional, Hsu, Cheng-Ting, additional, Hsu, Po-Yao, additional, Liu, Hung-Yin, additional, Huang, Ying-Chou, additional, Lin, Zu-Yau, additional, Chen, Shinn-Cherng, additional, Huang, Jee-Fu, additional, Dai, Chia-Yen, additional, Chuang, Wan-Long, additional, and Yu, Ming-Lung, additional

Published
2021
Full Text
View/download PDF

44. Comedications and potential drug-drug interactions with direct-acting antivirals in hepatitis C patients on hemodialysis

Author

Hsu, Po-Yao, primary, Wei, Yu-Ju, additional, Lee, Jia-Jung, additional, Niu, Sheng-Wen, additional, Huang, Jiun-Chi, additional, Hsu, Cheng-Ting, additional, Jang, Tyng-Yuan, additional, Yeh, Ming-Lun, additional, Huang, Ching-I, additional, Liang, Po-Cheng, additional, Lin, Yi-Hung, additional, Hsieh, Ming-Yen, additional, Hsieh, Meng-Hsuan, additional, Chen, Szu-Chia, additional, Dai, Chia-Yen, additional, Lin, Zu-Yau, additional, Chen, Shinn-Cherng, additional, Huang, Jee-Fu, additional, Chang, Jer-Ming, additional, Hwang, Shang-Jyh, additional, Chuang, Wan-Long, additional, Huang, Chung-Feng, additional, Chiu, Yi-Wen, additional, and Yu, Ming-Lung, additional

Published
2021
Full Text
View/download PDF

45. Role of hepatitis D virus in persistent alanine aminotransferase abnormality among chronic hepatitis B patients treated with nucleotide/nucleoside analogues

Author

Jang, Tyng-Yuan, primary, Wei, Yu-Ju, additional, Yeh, Ming-Lun, additional, Liu, Shu-Fen, additional, Hsu, Cheng-Ting, additional, Hsu, Po-Yao, additional, Liu, Ta-Wei, additional, Lin, Yi-Hung, additional, Liang, Po-Cheng, additional, Hsieh, Meng-Hsuan, additional, Ko, Yu-Min, additional, Tsai, Yi-Shan, additional, Chen, Kuan-Yu, additional, Lin, Ching-Chih, additional, Tsai, Pei-Chien, additional, Wang, Shu-Chi, additional, Huang, Ching-I., additional, Lin, Zu-Yau, additional, Chen, Shinn-Cherng, additional, Chuang, Wan-Long, additional, Huang, Jee-Fu, additional, Dai, Chia-Yen, additional, Huang, Chung-Feng, additional, and Yu, Ming-Lung, additional

Published
2021
Full Text
View/download PDF

46. Establishment of an outreach, grouping healthcare system to achieve microelimination of HCV for uremic patients in haemodialysis centres (ERASE-C)

Author

Yu, Ming-Lung, primary, Huang, Chung-Feng, additional, Wei, Yu-Ju, additional, Lin, Wen-Yi, additional, Lin, Yi-Hung, additional, Hsu, Po-Yao, additional, Hsu, Cheng-Ting, additional, Liu, Ta Wei, additional, Lee, Jia-Jung, additional, Niu, Sheng-Wen, additional, Huang, Jiun-Chi, additional, Hung, Tzu-Sui, additional, Yeh, Ming-Lun, additional, Huang, Ching-I, additional, Liang, Po-Cheng, additional, Hsieh, Ming-Yen, additional, Chen, Szu-Chia, additional, Huang, Jee-Fu, additional, Chang, Jer-Ming, additional, Chiu, Yi-Wen, additional, Dai, Chia-Yen, additional, Hwang, Shang-Jyh, additional, and Chuang, Wan-Long, additional

Published
2020
Full Text
View/download PDF

47. The applicability of non-invasive methods for assessing liver fibrosis in hemodialysis patients with chronic hepatitis C

Author

Lee, Jia-Jung, primary, Wei, Yu-Ju, additional, Lin, Ming-Yen, additional, Niu, Sheng-Wen, additional, Hsu, Po-Yao, additional, Huang, Jiun-Chi, additional, Jang, Tyng-Yuan, additional, Yeh, Ming-Lun, additional, Huang, Ching-I, additional, Liang, Po-Cheng, additional, Lin, Yi-Hung, additional, Hsieh, Ming-Yen, additional, Hsieh, Meng-Hsuan, additional, Chen, Szu-Chia, additional, Dai, Chia-Yen, additional, Lin, Zu-Yau, additional, Chen, Shinn-Cherng, additional, Huang, Jee-Fu, additional, Chang, Jer-Ming, additional, Hwang, Shang-Jyh, additional, Huang, Chung-Feng, additional, Chiu, Yi-Wen, additional, Chuang, Wan-Long, additional, and Yu, Ming-Lung, additional

Published
2020
Full Text
View/download PDF

48. Regorafenib for Taiwanese patients with unresectable hepatocellular carcinoma after sorafenib failure: Impact of alpha‐fetoprotein levels.

Author

Hsu, Po‐Yao, Cheng, Tzu‐Sheng, Chuang, Shih‐Chang, Chang, Wen‐Tsan, Liang, Po‐Cheng, Hsu, Cheng‐Ting, Wei, Yu‐Ju, Jang, Tyng‐Yuan, Yeh, Ming‐Lun, Huang, Ching‐I, Lin, Yi‐Hung, Wang, Chih‐Wen, Hsieh, Ming‐Yen, Hou, Nai‐Jen, Hsieh, Meng‐Hsuan, Tsai, Yi‐Shan, Ko, Yu‐Min, Lin, Ching‐Chih, Chen, Kuan‐Yu, and Dai, Chia‐Yen

Subjects
*REGORAFENIB, *SORAFENIB, *ALPHA fetoproteins, *TAIWANESE people, *PROGRESSION-free survival, *HEPATOCELLULAR carcinoma, *HAND-foot syndrome
Abstract

Background and Aims: Regorafenib has demonstrated its survival benefit for unresectable hepatocellular carcinoma (uHCC) patients in a phase III clinical trial. We aimed to assess the efficacy and tolerability of regorafenib and the predictors of treatment outcomes in Taiwanese patients. Methods: We analyzed the survival, best overall response, predictors of treatment outcomes, and safety for uHCC patients who had tumor progression on sorafenib therapy and received regorafenib as salvage therapy between March 2018 and November 2020. Results: Eighty‐six patients with uHCC were enrolled (median age, 66.5 years; 76.7% male). The median regorafenib treatment duration was 4.0 months (95% confidence interval [CI], 3.6–4.6). The most frequently reported adverse events were hand‐foot skin reaction (44.2%), diarrhea (36.0%), and fatigue (29.1%). No unpredictable toxicity was observed during treatment. The median overall survival (OS) with regorafenib was 12.4 months (95% CI, 7.8–17.0) and the median progression‐free survival (PFS) was 4.2 months (95% CI, 3.7–4.7). Of 82 patients with regorafenib responses assessable, 4 patients (4.9%) achieved a partial response, and 33 (40.2%) had stable disease, leading to a disease control rate (DCR) of 45.1% (n = 37). Patients possessing baseline AFP < 400 ng/ml exhibited a markedly longer median OS, median PFS, and higher DCR compared with their counterparts (15.7 vs. 8.1 months, 4.6 vs. 3.7 months, 60.9% vs. 27.5%, respectively). Despite possessing high baseline AFP levels, patients with early AFP response (>10% reduction at 4 weeks or >20% reduction at 8 weeks after regorafenib administration) exhibited comparable treatment outcomes to those with baseline AFP < 400 ng/ml. Conclusions: The results of this real‐world study verified the tolerability and efficacy of regorafenib treatment for uHCC patients who failed prior sorafenib therapy, especially for those with lower baseline AFP levels or with early AFP response. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results